Search Results - "Kim, D. W"

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 by Shaw, A.T., Riely, G.J., Bang, Y.-J., Kim, D.-W., Camidge, D.R., Solomon, B.J., Varella-Garcia, M., Iafrate, A.J., Shapiro, G.I., Usari, T., Wang, S.C., Wilner, K.D., Clark, J.W., Ou, S.-H.I.

“…In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC)…”
Get full text

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS by Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D.S.W., Yang, J.C.-H., Azrif, M., Mitsudomi, T., Park, K., Soo, R.A., Chang, J.W.C., Alip, A., Peters, S., Douillard, J.-Y.

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of…”
Get full text

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial by Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K.H., Lu, S., Shi, Y., Lee, D.H., Laskin, J., Kim, D.-W., Laurie, S.A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.

“…In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and…”
Get full text

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer by Niu, J., Maurice-Dror, C., Lee, D.H., Kim, D.-W., Nagrial, A., Voskoboynik, M., Chung, H.C., Mileham, K., Vaishampayan, U., Rasco, D., Golan, T., Bauer, T.M., Jimeno, A., Chung, V., Chartash, E., Lala, M., Chen, Q., Healy, J.A., Ahn, M.-J.

“…In this first-in-human phase 1 study (NCT02964013; MK-7684-001), we investigated the safety and efficacy of the anti-TIGIT (T cell immunoglobulin and ITIM…”
Get full text

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial by Herbst, R.S., Baas, P., Perez-Gracia, J.L., Felip, E., Kim, D.-W., Han, J.-Y., Molina, J.R., Kim, J.-H., Dubos Arvis, C., Ahn, M.-J., Majem, M., Fidler, M.J., Surmont, V., de Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E.H., Lubiniecki, G.M., Garon, E.B.

“…In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced…”
Get full text

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial by Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M

“…In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher…”
Get full text

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study by Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H.I., Ahn, J.S., Shaw, A.T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.

“…•Investigator-assessed PFS data in the ALEX study are now mature (53% of events in the alectinib arm).•Alectinib significantly prolonged PFS vs crizotinib…”
Get full text

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC by Ou, S.-H. I., Jänne, P.A., Bartlett, C.H., Tang, Y., Kim, D.-W., Otterson, G.A., Crinò, L., Selaru, P., Cohen, D.P., Clark, J.W., Riely, G.J.

“…Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We…”
Get full text

The Luminosity Function of X-Ray-selected Active Galactic Nuclei: Evolution of Supermassive Black Holes at High Redshift by Silverman, J. D, Green, P. J, Barkhouse, W. A, Kim, D.-W, Kim, M, Wilkes, B. J, Cameron, R. A, Hasinger, G, Jannuzi, B. T, Smith, M. G, Smith, P. S, Tananbaum, H

“…We present a measure of the hard (2-8 keV) X-ray luminosity function (XLF) of AGNs up to [image]. At high redshifts, the wide area coverage of the Chandra…”
Get full text

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias by Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

“…Several tyrosine kinase inhibitors have activity in Ph-positive chronic and acute leukemia, but resistant disease and unacceptable side effects may limit…”
Get full text

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial by Griesinger, F., Curigliano, G., Thomas, M., Subbiah, V., Baik, C.S., Tan, D.S.W., Lee, D.H., Misch, D., Garralda, E., Kim, D.-W., van der Wekken, A.J., Gainor, J.F., Paz-Ares, L., Liu, S.V., Kalemkerian, G.P., Houvras, Y., Bowles, D.W., Mansfield, A.S., Lin, J.J., Smoljanovic, V., Rahman, A., Kong, S., Zalutskaya, A., Louie-Gao, M., Boral, A.L., Mazières, J.

“…RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET…”
Get full text

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) by Blumenschein, G.R., Smit, E.F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N.H., Kim, J.-H., Mazieres, J., Kim, S.-W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F.S., Jänne, P.A.

“…KRAS mutations in non-small-cell lung cancer (NSCLC) are associated with poor prognosis. Trametinib, a selective inhibitor of MEK1/MEK2, demonstrated similar…”
Get full text

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial by Lee, S.-H., Lee, J.-K., Ahn, M.-J., Kim, D.-W., Sun, J.-M., Keam, B., Kim, T.M., Heo, D.S., Ahn, J.S., Choi, Y.-L., Min, H.-S., Jeon, Y.K., Park, K.

“…Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed…”
Get full text

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up by Larson, R A, Hochhaus, A, Hughes, T P, Clark, R E, Etienne, G, Kim, D-W, Flinn, I W, Kurokawa, M, Moiraghi, B, Yu, R, Blakesley, R E, Gallagher, N J, Saglio, G, Kantarjian, H M

“…Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients compares nilotinib and imatinib in patients with newly diagnosed chronic…”
Get full text

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia by Steegmann, J L, Baccarani, M, Breccia, M, Casado, L F, García-Gutiérrez, V, Hochhaus, A, Kim, D-W, Kim, T D, Khoury, H J, Le Coutre, P, Mayer, J, Milojkovic, D, Porkka, K, Rea, D, Rosti, G, Saussele, S, Hehlmann, R, Clark, R E

“…Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and…”
Get full text

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer by Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S.W., Kim, J.S., Park, K., Lee, M.Y., Heo, D.S.

“…Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate…”
Get full text

Occurrence of both unipolar memory and threshold resistance switching in a NiO film by Chang, S H, Lee, J S, Chae, S C, Lee, S B, Liu, C, Kahng, B, Kim, D-W, Noh, T W

“…We observed two types of reversible resistance switching (RS) effects in a NiO film: memory RS at low temperature and threshold RS at high temperature. We were…”
Get full text

Gas sensing properties of defect-controlled ZnO-nanowire gas sensor by Ahn, M.-W., Park, K.-S., Heo, J.-H., Park, J.-G., Kim, D.-W., Choi, K. J., Lee, J.-H., Hong, S.-H.

“…The effect of oxygen-vacancy-related defects on gas-sensing properties of ZnO-nanowire gas sensors was investigated. Gas sensors were fabricated by growing ZnO…”
Get full text

Relationship between stretch formability and work-hardening capacity of twin-roll cast Mg alloys at room temperature by Kang, D.H., Kim, D.-W., Kim, S., Bae, G.T., Kim, K.H., Kim, Nack J.

“…The stretch formability of twin-roll cast (TRC) Mg alloys at room temperature has been investigated in relation to their work-hardening capacity. It is shown…”
Get full text

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study by Lee, J.K., Shin, J.-Y., Kim, S., Lee, S., Park, C., Kim, J.-Y., Koh, Y., Keam, B., Min, H.S., Kim, T.M., Jeon, Y.-K., Kim, D.-W., Chung, D.H., Heo, D.S., Lee, S.-H., Kim, J.-I.

“…The mechanism of primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer…”
Get full text